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Mucoepidermoid carcinoma (MEC) harbors a recurring t(11;19) 
translocation with an associated novel fusion oncogene-MECT1-MAML2. The 
CRTC1-MAML2oncogene disrupts normal cell-cycle and differentiation, 
contributing to tumor development. The objectives of this study were to establish 
the incidence of CRTC1-MAML2 fusion in Serbian patients and estimate its 
relevance as a genetic marker of MEC behavior. In this retrospective study, 20 
cases of MEC of salivary glands were tested for the presence of CRTC1-MAML2 
fusion using reverse transcriptase-polymerase chain reaction. Clinicopathological 
parameters and survival data were examined in relation to fusion status. The 
CRTC1-MAML2 fusion was detected in 40% of MECs and its presence was 
associated exclusively with low-intermediate grade tumor histology (P = 0.02) 
and favorable clinical outcome, with 100 % overall survival rate (P=0.046).  The 
study has shown that the presence of the CRTC1-MAML2 fusion can serve as an 
additional diagnostic and prognostic marker for mucoepidermoid carcinomas.  
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INTRODUCTION 
The World Health Organization recognized twenty-four types of benign and malignant 
salivary gland tumors (EVESON et al., 2005). Mucoepidermoid carcinoma (MEC) represents 5% 
of all salivary gland tumors and 20% of salivary gland malignancies (GOODE et al., 2005).  
Clinical monitoring of this tumor and its outcome prediction are complicated due to biological 
diversity and clinical heterogeneity (BELL et al., 2005). Seventy years after the first identification 
of MEC, a unique, standardized grading system does not exist (LUNA, 2006). Hence, “failure to 
diagnose” or “erroneous diagnosis” are not uncommon, leading to delayed or missed therapy or 
treatment and wrong prognosis. In other words, MEC remains a considerable challenge for 
pathologists, and additional molecular markers that could contribute to better diagnosis and 
predict the natural history of these tumors are needed.  
Genetic research of mucoepidermoid carcinomas was mainly focused on a non-random 
t (11;19) (q21;p13) reciprocal translocation  which appeared as a possible hallmark of  MEC. 
This translocation generates CRTC1-MAML2 fusion in which the CREB-binding domain of the 
CREB coactivator CRTC1 (also known as MECT1, TORC1 or WAMTP1) is fused to the 
transactivation domain of the Notch coactivator MAML2 (MITELMAN, 2000). It seems that 
MECT1–MAML2 fusion induced activation of CREB is critical for cell transformation (TONON 
et al., 2003; WU et al., 2005). A CRTC3-MAML2 fusion gene resulting in the same MEC 
phenotype as CRTC1-MAML2 has been described as well (FEHR et al., 2008). 
The incidence of CRTC1–MAML2 fusion in salivary gland MEC reported in different 
studies varied considerably (between 38%–and 81%) (OKABE et al., 2006; MIYABE et al., 2009, 
JEE et al., 2013) and it was assumed that the t (11; 19) gene fusion product was present only in 
low- and intermediate-grade MECs (OKABE et al., 2006; SEETHALA et al. 2010). Conversely, 
other studies have shown that the fusion gene could be found in high grade (HG) MEC as well, 
which sparked a debate on its prevalence and relevance (TIRADO et al., 2007; CHENEVERT et al., 
2011, NAKANO et al., 2013). The aim of this research was to assess the relevance of CRTC1-
MAML2 fusion as a potential genetic marker of tumor behavior in MECs in Serbian population.  
 
MATERIALS AND METHODS 
Patients and specimens 
Formalin-fixed, paraffin-embedded specimens of 52 mucoepidermoid carcinomas of 
salivary glands resected in the period 2001-2010 at the Clinic of Maxillofacial Surgery, School 
of Dental Medicine, University of Belgrade were available for the analysis.  Prior to molecular 
genetics analyses, the cases were once more carefully reviewed in 2012 by two independent 
pathologists (Z.T. and T.L.) according to the criteria of the WHO Classification for Pathology 
and Genetics of Head and Neck Tumors (EVESON et al., 2005). Upon revision, 15 cases of 
alleged high grade (HG) MEC were excluded from further analysis.  After RNA extraction 
additional 17 cases had to be excluded because of insufficient RNA quantity or quality. 
Evaluable PCR-results were obtained for 20 cases of MEC. The study was approved by the 
Ethical Committee of the School of Dental Medicine, University of Belgrade (IRB: 36/10) and 
written informed consent was obtained from each patient in accordance with the Declaration of 
Helsinki. 
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Clinicopathological data   
The following parameters were recorded for every patient: age, sex, primary tumor site, 
tumor size, metastases to regional lymph nodes, clinical stage, histological grade, and follow-up 
and the tumor specimens were histologically classified according to a 3-grade system described 
by BRANDWEIN et al. (2001). The tumor grade was determined from the sum of the point values 
assigned to each of the following histologic elements: cystic component, neural invasion, 
necrosis, mitosis, and anaplasia. 
 
CRTC1-MAML2 fusion detection   
The CRTC1-MAML2 fusion transcript was detected using one step reverse 
transcription-polymerase chain reaction (RT-PCR). To this end, microtome sections were 
prepared from paraffin-embedded tissue blocks and one of the sections was stained with 
hematoxylin/eosin (HE) for microscopic inspection by a pathologist. Tumor containing tissue 
was then microdissected, deparaffinized and RNA was extracted, using the RNeasy FFPE Kit 
(Qiagen, Hilden, Germany). The CRTC1-MAML2 specific RT-PCR was performed, using the 
Qiagen OneStep RT-PCR kit according to the manufacturer instructions (Qiagen, Hilden 
Germany). Primers used for detecting the CRTC1-MAML2 fusion transcript were the following:  
 
MECT1 For 5’-GCCTTCGAGGAGGTCATGA-3’ 
MAML2 Rev 5’-CTTGCTGTTGGCAGGAGA-3’. 
As a positive control for each sample wild type MAML2 was also amplified using the primers:  
MAML2 For 5’-GTAGCAATAATGGTGGCAGT-3’ 
MAML2 Rev 5’-CTTGCTGTTGGCAGGAGA-3’. 
 
PCR reactions were performed in an ABI 2720 Thermal Cycler (Applied Biosystems, Foster 
City, USA) using the following amplification conditions: after an initial denaturation step at 
94°C for 3 min, 35 cycles of 94°C for 45 sec, 55 °C for 30 sec, and 72° C for 30 sec were run 
followed by a final extension step of 10 min at 72°C. PCR products were run and analyzed using 
the ABI 3130 Genetic Analyzer and the Gene Mapper v. 4.0 Software (Applied Biosystems, 
Foster City, USA).  
 
Statistical analysis  
For general information about the sample usual descriptive statistic tests were used. The 
survival rate was calculated with the Kaplan–Meier method. All analyses were performed with 
the statistical package SPSS, version 18 (IMB statistics software). 
 
RESULTS 
Clinicopathological characteristics of MECs and association with CRTC1-MAML2 
fusion 
The study sample included 12 male and 8 female patients diagnosed with MEC, with 
the age ranging from 15 to 81 years (mean 55.5 years). Primary MEC localization were major 
salivary glands in all 20 cases (parotid gland, submandibular and sublingual). Out of the 20 
confirmed MECs 7 had more than 2 cm in diameter and they were classified as clinical stages III 
and IV. Only 3 showed metastases to the regional cervical lymph nodes. Histologically, 9 cases 
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were classified as low grade, 5 as intermediate grade and 6 as high grade. The CRTC1-MAML2 
fusion transcript was detected in 8 (40%) of the 20 MEC cases. Correlation of CRTC1-MAML2 
fusion with clinicopathological features of MEC is given in Table 1. The fusion positive cases 
were associated with low-intermediate histological grade (P = 0.02).  Of the five factors 
constituting the histological grade, two correlated significantly with the presence of the fusion 
transcript- absence of necrosis (P= 0.024) and a lesser degree of anaplasia (P= 0.024).  
Table 1. Distribution of epidemiological, clinical and histological characteristics of 20 MEC patients in 
relation to the presence/abscence of CRTC1-MAML2fusion 
Abbreviations:  NS, not significant; HPF, high-powered field 
           Variable 
 
MECT1 – MAML2 
fusion 
P 
Positive 
(n=8) 
Negative 
(n=12) 
Age (years) Mean 50,25 59 NS 
Sex Male 3 9 NS 
Female 5 3 
Tumour site Major 8 12 NS 
Minor 0 0 
Tumour size >20 mm 7 7 NS 
<20 mm 1 5 
Nodal status Positive 0 3 NS 
Negative 8 9 
Clinical stage I, II 7 8 NS 
III, IV 1 4 
Histological findings 
Histological grade 
Low 7 2 
0.02 Intermediate 1 4 
High 0 6 
Cystic component >20% 4 6 NS 
<20% 4 6 
Neural invasion Positive 0 2 NS 
Negative 8 10 
Necrosis Positive 0 6 0.024 
Negative 8 6 
Mitoses >4 ⁄ 10 HPF 2 7 NS 
<3 ⁄ 10HPF 6 5 
Anaplasia 
Positive 0 6 
0.024 
Negative 8 6 
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Factors affecting disease-free and overall survival 
 
The follow-up was 138 months. At the last medical visit 10 patients were alive with no 
evidence of disease and 4 were alive with the disease. Among patients who died, 4 died from 
disease and 2 from other cause.  None of the patients with CRTC1-MAML2 fusion-positive MEC 
died of the tumor.   
Kaplan-Meier analysis for disease-free survival, showed that MEC patients with 
positive CRTC1-MAML2 fusion transcript had 100 % survival rate (P= 0.002) (Table 2). Cases 
negative for the fusion had the following survival rates: 89% in histological grade I, 60% in 
grade II and 17% in grade III. As expected, patients with advanced tumor size (P=0,001) and 
clinical stage III/IV (P=0.003) showed low rate of disease-free survival. Low rate of disease-free 
survival was also observed in cases with tumor necrosis (P=0.001), neural invasion (P=0,006), 
anaplasia (P=0.003) and increased mitotic index (P=0,003). The Kaplan-Meier analysis showed 
a statistically significant association between several variables and survival rates (Table 2), 
including the fusion status (Fig. 1).  
 
 
 
 
Figure 1. Kaplan Meier representation of MEC patients overall survival in relation to the presence/absence 
of CRTC1-MAML2 fusion ranscript. 
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Table 2. Survival analysis in MEC patients in relation to clinical, histological and genetic data 
Abbreviations:  *NS, not significant; †HPF, high-powered field 
 
DISCUSSION 
Specific chromosomal translocations are commonly observed in hematopoietic and 
mesenchymal stromal tumors and define distinct clinicopathological entities. Interestingly, 
translocations are rather an exception than a rule in epithelial tumors, and mucoepidermoid 
carcinomas fall into less than 1% of all epithelial cancers with a recurrent, pathogenic 
chromosomal aberration (MITELMAN,
 
2000). According to STENMAN (2005), FEHR et al., (2009) 
and BHAIJEE et al (2011) CRTC1-MAML2 fusion might define a distinct clinicopathological 
subset of mucoepidermoid carcinomas. This opinion is corroborated by the present study which 
showed that the CRTC1-MAML2 fusion is associated with low-intermediate grade histology and 
favorable clinical outcome. 
Variable Variable's 
value 
Disease free survival (P) Overall survival (P) 
MEC 
(n=20) 
MEC 
(n=20) 
Tumor size >20 mm 0.001 0.008 
<20 mm 
Nodal status Positive NS NS 
Negative 
Clinical stage I, II  0.003 0.031 
III, IV 
Histological 
grade 
Low  
0.006 NS Intermediate 
High 
Cystic component >20% NS NS 
<20% 
Neural invasion Positive 0.006 NS 
Negative 
Necrosis 
Positive 
0.001 
 
0.002 
 
Negative 
Mitoses 
>4 ⁄ 10 HPF† 
 
<3 ⁄ 10HPF 
0.003 0.004 
Anaplasia Positive 0.003 NS 
Negative 
MECT1-MAML2 Positive 0.002 0.046 
Negative 
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The CRTC1-MAML2 fusion transcript was detected in 40% of Serbian patients with 
MEC which is in agreement with the study of OKABE et al. (2006) who found 34% of fusion 
positive cases in their MEC sample, but it is a significantly lower percentage than reported by 
TIRADO et al. (2007), SCHWARZ et al. (2011), JEE et al. (2013). Our results demonstrated that the 
MECT1–MAML2 fusion was associated with low-intermediate grade tumor histology and a good 
prognosis which is also in agreement with other studies (OKABE et al., 2006; MIYABE et al., 
2009). Similarly to our results, other groups have also shown that the fusion-positive cases had 
smaller tumor size, lower frequency of nodal metastasis and less advanced clinical stage (OKABE 
et al., 2006; OKUMARA et al., 2011). In addition, OKABE found that patients with fusion-positive 
tumors had significantly greater overall survival compared to fusion-negative patients. In this 
study patients with fusion-positive MECs also showed 100% overall survival. All high grade 
MECs were negative for the fusion transcript and all the patients with HG MEC died within the 
first five years after the diagnosis.  
Yet, some authors found a relatively high prevalence of fusion transcripts in high grade 
MECs (TIRADO et al., 2007; MIYABE et al., 2009).
 
One of the possible reasons for this 
discrepancy is the absence of a uniform classification system and frequent misdiagnosis of 
various tumors (such as squamous cell carcinoma or adenosquamous carcinoma), as “high-
grade” MECs (BRANDWEIN et al., 2000; CHENEVERT et al., 2011).  Two-tiered and three-tiered 
systems of MEC grading are in use (BAI et al. 2013), which may lead to confusion. BEHBOUDI et 
al. (2006) and OKUMURA (2011) among others suggested the introduction of molecular 
classification of MECs in which MECT1–MAML2 fusion status would serve as an additional 
diagnostic tool for distinguishing molecular subtypes of this tumor. 
 
The results of a recent study using high-resolution array-based comparative genomic 
hybridization revealed that low-grade MECs had significantly fewer copy number alterations 
compared to high grade MECs and regardless of their histological grade, fusion -positve MECs 
had a much more stable genome then fusion-negative MECs (JEE et al., 2013).  
The great majority of MECs are treated by surgical resection with radiation as an 
adjunct therapy (SPIRO, 1998). Determination of CRTC1-MAML2 fusion could have clinical 
benefits. Preoperative RT-PCR analysis using tumor material obtained by fine-needle aspiration 
(JAYARAM et al., 1994) could be clinically useful and improve therapeutic strategies.  A new 
protocol should be approved indicating that radical surgical resection with a postoperative 
radiotherapy is required for aggressive tumors such as fusion negative HG MECs. On the other 
hand, fusion positive MECs should undergo a less radical surgical resection with preservation of 
the facial nerve and without postoperative radiotherapy.  It has been shown that expression of 
CRTC1-MAML2 fusion is essential for tumor growth in fusion positive carcinomas (KOMIYA et 
al. 2006), making the fusion a potential therapeutic target. 
There is a limited number of publications on the CRTC1-MAML2 fusion and its possible 
role as a diagnostic and prognostic tool obtained on European populations. This is the first report 
on the prevalence of CRTC1-MAML2 fusion in Serbian patients with mucoepidermoid 
carcinomas and it represents a significant contribution to the extremely scarce genetics of 
salivary gland tumors in Serbian population (MILAŠIN et al. 1993, NIKOLIĆ et al. 2013). 
In summary, the fusion may be considered as a molecular marker in this heterogeneous 
group of salivary gland tumors, i.e. fusion positive and fusion negative MECs should be viewed 
as distinct clinicopathological entities and treated with apposite therapies.  
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Izvod 
Kod velikog broja mukoepidermoidnih karcinoma (MEK) pljuvačnih žlezda detektovana je 
t(11;19) hromozomska translokacija koja vodi nastanku CRTC1-MAML2 fuzionog produkta sa 
onkogenom aktivnošću koji remeti ćelijski ciklus i diferencijaciju dovodeći do razvoja tumora. 
Ciljevi ove studije bili su da se ispita učestalost CRTC1-MAML2 fuzije kod naših pacijenata 
obolelih od MEK-a i da se proceni značaj fuzije kao potencijalnog markera biološkog ponašanja 
ovih maligniteta. U ovoj retrospektivnoj studiji 20 slučajeva MEK-a bilo je testirano na prisustvo 
CRTC1-MAML2 fuzionog transkripta koristeći reverznu transkriptazu- lančanu reakciju 
polimeraze (RT-PCR). Ispitivana je korelacija CRTC1-MAML2 fuzionog statusa sa kliničko-
patološkim karakteristikama tumora kao i vreme preživljavanja pacijenata sa MEK-om. CRTC1-
MAML2 fuzija je detektovana u 40% slučajeva i pokazana je njena povezanost sa niskim 
odnosno srednjim histološkim gradusom karcinoma (P = 0.02), kao i sa 100%-nom stopom 
preživljavanja (P=0.046). CRTC1-MAML2 fuzioni status u mukoepidermoidnom karcinomu 
pljuvačnih žlezda pokazao se kao koristan dopunski parameter za pouzdaniju dijagnozu i 
prognozu.  
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